



IFCT-2203 TAXIO

Phase II chemotherapy + immunotherapy (durvalumab)

IFCT-2105 LURBICLIN

Cohort lurbinectedin Expanded Access Program (EAP)

IFCT-1905 CLINATEZO

Cohort atezolizumab + chemotherapy Expanded Access Program (EAP)

Pleural mesothelioma IFCT-1901 IND227 Phase II/IIIR, chemotherapy + Immunotherapy (pembrolizumab)

Recruiting

In follow-up

IFCT-1104 RYTHMIC Observatory of patients with thymic epithelial tumor (INCa network) GCO-001 NIPINEC Phase IIR.

Neuroendocrine tumors Immunotherapy

(nivolumab +/- ipilimumab)